Page 462 - Essential Haematology

448 / Index

platelet(s) (continued) Pneumocystis carinii, allogeneic idiopathic thrombocytopenic
increased destruction 334–40 stem cell transplantation purpura 415–16
lifespan 316 309, 310 iron defi ciency anaemia 414
myelodysplasia 217 poikilocytosis 29 iron requirements 41
normal values 425 point mutations 157, 158 physiological anaemia 414
nucleotide level measurement polycythaemia 18, 22, 203 sickle cell anaemia 103
343 apparent 203, 208 thrombocytopenia 414,
plasma membrane 317, 318 classifi cation 203 415–16
plug formation 324–5 diff erential diagnosis 208 thrombosis 416
procoagulant activity 320 malignancy 382 warfarin contraindication 375,
production 315–16, 317 neonatal 418 416
failure 333–4 primary 203 primary central nervous system
prostacyclin synthesis 319 secondary 203, 208, 382 lymphoma 269
release reactions 318, 320 polycythaemia vera 203–8 prion diseases, blood transfusion
rolling 324 clinical features 204–5, 206 403, 404
storage granules 318, 321 course 208 procoagulant factors, infl ammation
structure 316, 317, 318 diagnosis 204 369
thromboxane synthesis 319 JAK2 mutation 203, 204, 205 programmed cell death see apoptosis
for transfusion 409 laboratory fi ndings 205, 206 prolymphocytic leukaemia (PLL)
platelet aggregation studies 343 prognosis 208 241, 242
platelet concentrates 410–11 treatment 206–8 pronormoblasts 16
platelet counts 27, 316 venous thrombosis 369 prostacyclin 320
post-splenectomy 148 polymerase chain reaction (PCR) synthesis 319
platelet-derived growth factor factor V Leiden mutation 366 prostaglandin synthesis 324
(PDGF) 318, 320, 321 haematological malignancies protein 4.1 22
platelet function analysis-100 (PFA- 160, 164, 165 protein C 325, 326
100) 328, 343 haemoglobin genetic disorder infl ammation 369
platelet function disorders 340–3 diagnosis 105–6, 107 neonates 418
acquired 341–2 polymyalgia rheumatica 385 thrombophilia screening 370
diagnosis 342–3 post-thrombotic syndrome 377 protein C concentrate 411
hereditary 340–1 post-transfusion circulatory overload protein C defi ciency 367
laboratory tests 342 407–8 neonates 418
platelet transfusions 343 post-transfusion hepatitis 408 protein S 325, 326
platelet transfusions 410–11 post-transfusion purpura 408 thrombophilia screening 370
allogeneic stem cell thrombocytopenia 337 prothrombin gene analysis,
transplantation 310 post-transfusional iron overload thrombophilia screening
autoimmune thrombocytopenic 53–4, 55, 95, 408 370
purpura 336 post-transplant lymphoproliferative prothrombin time (PT) 327–8
haematological malignancies 167 disorders 429 neonates 418
massive transfusion syndrome pregnancy 414–16 thrombophilia screening 370
360 coagulation 414, 416 vitamin K defi ciency 355
platelet function disorders 343 disseminated intravascular prothrombinase complex 322
refractoriness 410–11 coagulation 416 proto-oncogenes 154–5
thrombocytopenia 343 erythropoiesis requirements 414 protoporphyrin 20
Plummer–Vinson syndrome 39, 41 folate defi ciency 414–15 protozoal infections
pluripotent stem cells 5–6, 8 folic acid prophylaxis 70–1 haematological malignancies
PML gene 182–3, 186 haemostasis 416 154
PML-RARα fusion protein 182–3 heparin 416 see also malaria